Skip to main content

Table 2 Characteristics of studies included in meta-analysis

From: A systematic review and meta-analysis of long COVID symptoms

First author

Publication year

Study type

Sample size

Country

Percent of women

Ethnicity

Follow-up time, months

p value

Akter

2020

Cross-sectional study

734

Bangladesh

24%

/

1

/

Huang

2021

Cohort study

1733

China

48%

/

5

/

Humphreys

2021

Qualitative study

18

UK

50%

55.6% White

16.7% White other

16.7% Asian

5.6% Black

5.6% Mixed

1

/

Simani

2021

Cross-sectional study

120

Iran

33.3%

/

6

/

Taylor

2021

Qualitative study

13

UK

84.6%

84.6% White British

/

/

Felipe

2020

Cross-sectional study

46

Brazil

54.3%

/

4

/

Hopkins

2020

Cohort study

382

UK

74.6%

/

1

Loss of smell p < 0.001

Petersen

2020

Cohort study

180

Faroe Islands

54.4%

/

4

/

Iqbal

2021

Cross-sectional study

158

Pakistan

55.1%

/

1

/

Poncet-Megemont

2020

Cohort study

139

France

62.6%

/

1

/

Trevisan

2021

Observational study

1618

Italy, Spain, and Norway

55%

/

6

/

Klein

2021

Cohort study

103

Israel

37.9%

/

6

/

Munro

2020

Cross-sectional study

138

UK

12.5%

/

/

/

Chopra

2020

Cohort study

488

USA

/

51.6% Black

37.3% White

11.1%other/unknown

0r

4.4% Hispanic

86.7% Non-Hispanic

9.3% Unknown

2

/

Putri

2021

Survey

109

Taiwan

44.95%

100% Asian

0.25

/

Liu

2020

Cross-sectional study

675

China

53%

/

1

/

Tenforde

2020

Cross-sectional study

292

USA

52%

34.8% White, non-Hispanic

17% Black, non-Hispanic

36.3% Hispanic

11.9% other

0.5

p = 0.01

Sykes

2021

Cross-sectional study

134

UK

34.3%

91% White

1.5% Black

6% Asian

1.5% Mixed/other

4

/

Townsend

2021

Cohort study

40

Ireland

90%

/

5

/

Writing Committee for the COMEBAC Study Group, 2021 [6]

2021

Cohort study

478

France

42.1%

/

4

/

Augustin

2021

Cohort study

353

Germany

53.5%

/

7

/

Duncan

2021

Survey

NA

Scotland

/

/

/

/

Osikomaiya

2021

Cohort study

274

Nigeria

33.9%

/

0.5

/

Orrù

2021

Cross-sectional study

152

Italy

/

/

3 + 

Insomnia p < 0.05

quality of life p < 0.05

Pujari

2021

Cross-sectional study

94

India

26.6%

/

0.5

/

Frontera

2021

Prospective study

382

USA

35%

Hispanic 15%/22%

Non-Hispanic 62%/59%

Prefer not to answer 23%/19%

6

/

Holmes

2021

Cohort study

27

Australia

/

/

6

/

Townsend

2020

Longitudinal study

111

Ireland

63%

/

3

/

Estiri

2021

Cohort study

57,622

USA

/

/

3–6, 6–9

/

Chevinsky

2021

Cohort study

148,892

USA

57%

40.9% White

25.2% Black

2.4% Asian

21% Hispanic

10.6% Others

1–4

/

Pereira

2021

Cohort study

38

UK

84%

BAME group 37%

7

/

Romero-Duarte Á

2021

Cross-sectional study

797

Spain

46.3%

/

6

/

Graham

2021

Cohort study

50

USA

66%

88% White, 4% Black or African American, 4% Asian,

0% American Indian or Alaskan Native, 4% Other

Or

Hispanic or Latino 12%

Not Hispanic or Latino 88%

4

/

Trinkmann

2021

Cross-sectional study

246

Germany

56.1%

/

2

p < 0.01

Nguyen

2021

Cohort study

125

France

55.2%

/

7

/

Vrillon

2021

Cohort study

125

France

58.4%

/

0.7

/

Modi

2021

Qualitative study

131

USA

47%

71% White(non-Hispanic)

7% White (Hispanic)

8% Black

2% Asian

1% American Indian

8% Multiracial

4% other (Hispanic)

6

/

Pasquini

2021

Cross-sectional study

26

Italy

65.4%

/

4

/

Boscolo-Rizzo

2021

Cohort study

183

Italy

54.6%

/

6

/

Capelli

2021

Cohort study

55

Italy

64%

/

8

/

Yvonne

2020

Cross-sectional study

2113

Netherlands and Belgium

85%

/

2

p < 0.001

Raman

2021

Cohort study

58

UK

41.4%

BAME group 22.4%

2

p < 0.0001 to 0.044

Swapna Mandal

2020

Cross-sectional study

384

UK

38%

38.8% British Caucasian

17.1% Other Caucasian

6.5% British Asian

10.3% Other Asian

6.8% Black British

7.6% Other black

13.9% Other ethnicity

2

p < 0.0001 for all symptoms

Marcel S. Woo

2020

Cross-sectional study

18

Germany

57.9%

/

3

/

Puntmann

2020

Cohort study

100

France

47%

/

2.5

/

Bellan

2021

Cohort study

238

Italy

59.7%

/

4

/

Stavem

2020

Cross-sectional study

451

Norway

56%

/

3

p < 0.001

Małek

2021

Cohort study

26

Poland

81%

/

1.5

/

Printza

2020

Cross-sectional study

90

Greece

41.1%

/

1

/

  1. P value (*) P value < 0.05 represents a significant improvement in symptoms at follow-up time compared to onset